CAMP and hepatocellular carcinoma: Although the detailed mechanism by which 1,25(OH)2D3 inhibits HCC metastasis is unclear, here for the first time, we revealed that hCAP18/LL-37 may be an important factor which suppresses the therapeutic benefit of 1,25(OH)2D3 in HCC tumors by promoting metastasis, which further supports the hypothesis that hCAP18/LL-37 may be an important target which can improve the anticancer activity of 1,25(OH)2D3 in HCC therapy.